The Ohio State University Comprehensive Cancer Center (OSUCCC) is currently in its 39th year as an NCI designated CCC, having received an ?exceptional? overall merit descriptor following its last review in 2010 and now requesting continued federal support for the next five years. Dr. Caligiuri continues in his twelfth year as the OSUCCC Director and his seventh year as CEO of OSU's freestanding James Cancer Hospital. The OSUCCC mission remains to reduce cancer morbidity and mortality through continued basic, translational and clinical research. The 222 OSUCCC full, associate or introductory members are currently served by 14 shared resources and are distributed among our five Research Programs which are: Cancer Control, Translational Therapeutics (formerly Experimental Therapeutics), Molecular Biology and Cancer Genetics, Molecular Carcinogenesis and Chemoprevention and a new Leukemia Research Program. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach, from etiology through prevention, treatment and survivorship among the major cancers afflicting its population ? lung, colorectal, breast, and prostate. This is done by addressing risky behaviors (tobacco use, obesity, HPV infection and lack of screening) and the higher incidence of and mortality from cancers among the following groups: the poor; the underserved populations of Ohio Appalachia; and inner city African-Americans. Since the last CCSG competitive renewal, the OSUCCC has shown significant growth as demonstrated by: 1) the recruitment of 145 faculty focused in basic, translational and clinical cancer research and cancer medicine, 58 of whom have become OSUCCC members; 2) the addition of 1,326,300 nsf of new space under the full control of the OSUCCC Director at a cost of $1.2 billion and including a new 1.1 million nsf James Cancer Hospital; 3) obtaining a $100M HRSA grant award to construct a state-of-the-art Radiation Oncology Center in the new James Cancer Hospital; 4) a 51% increase in patient accrual to interventional therapeutic trials reflective of robust growth in solid tumor research; 5) the addition of 2 new shared resources at an institutional investment of over $2 million; 6) strong team science as demonstrated by a 12.5% increase in NCI programmatic grant funding (as a fraction of our nearly $45 million in total direct NCI funding); 7) an increase in the mean percent NCI funding proportion to total CCSG funding for our five research programs from 51% to 61%, reflective of increased cancer focus; 8) enhanced collaborative research as demonstrated by a publication portfolio in which 64% of manuscripts are multi-institutional and 84.4% are collaborative (i.e., inter-, intra-programmatic or multi-institutional); and 9) preclinical and clinical development of two agents, one of which changed the landscape in cancer and both of which were subsequently FDA approved. With new recruits and resources in place and building on the momentum of our research work to date, the OSUCCC is poised in these coming five years to take significant steps toward achieving our mission and ultimately our vision of a cancer-free world.

Public Health Relevance

OVERALL NARRATIVE The Ohio State University Comprehensive Cancer Center (OSUCCC) is a matrix cancer center that integrates and leverages all of the resources of the University to achieve its broad vision of creating a cancer free world. The OSUCCC addresses the public health needs of the catchment area (the state of Ohio) through research and outreach. Research conducted within the five OSUCCC Programs focuses on ways to reduce the higher rates of lung, breast, CRC and prostate cancer as well as the higher prevalence of risky behaviors such as lack of screening, obesity, high tobacco use, and lack of HPV vaccine. Outreach efforts through the OSUCCC address the needs of underserved populations - lower education; poor; inner city African American; rural and urban Hispanic; Appalachian; rural; Amish; and Somali - by providing targeted, culturally appropriate education activities, free cancer screenings, patient navigation, community networking, environmental scans, community gardening, and addressing policy issues (eg, tobacco-free campus).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016058-41S1
Application #
9378861
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Marino, Michael A
Project Start
1997-09-12
Project End
2020-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Dalton, William S; Sullivan, Daniel; Ecsedy, Jeffrey et al. (2018) Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clin Pharmacol Ther 104:23-26

Showing the most recent 10 out of 2602 publications